Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
BackgroundThe present study was conducted to evaluate the efficacy and safety of anlotinib as third-line or above therapy for patients with advanced or metastatic gastric cancer.MethodsPatients with advanced or metastatic gastric cancer who have failed from second-line treatment and treated with anl...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2022-07-01
|
| Reeks: | Frontiers in Oncology |
| Onderwerpen: | |
| Online toegang: | https://www.frontiersin.org/articles/10.3389/fonc.2022.885350/full |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|